PARP inhibition in BRCA-mutated breast and ovarian cancers

被引：44

作者：

Chan, Stephen L. ^{[1
]}

Mok, Tony

机构：

[1] Chinese Univ Hong Kong, State Key Lab S China, Sir YK Pao Ctr Canc, Dept Clin Oncol,Hong Kong Canc Inst, Hong Kong, Hong Kong, Peoples R China

来源：

LANCET | 2010年 / 376卷 / 9737期

关键词：

POLY(ADP-RIBOSE) POLYMERASE; PHASE-III; TUMORS;

D O I：

10.1016/S0140-6736(10)61119-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：211 / 213

页数：3

共 17 条

[1] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].

Audeh, M. William ;

Carmichael, James ;

Penson, Richard T. ;

Friedlander, Michael ;

Powell, Bethan ;

Bell-McGuinn, Katherine M. ;

Scott, Clare ;

Weitzel, Jeffrey N. ;

Oaknin, Ana ;

Loman, Niklas ;

Lu, Karen ;

Schmutzler, Rita K. ;

Matulonis, Ursula ;

Wickens, Mark ;

Tutt, Andrew .

LANCET, 2010, 376 (9737) :245-251

[2] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [J].

Bang, Y. ;

Kwak, E. L. ;

Shaw, A. T. ;

Camidge, D. R. ;

Iafrate, A. J. ;

Maki, R. G. ;

Solomon, B. J. ;

Ou, S. I. ;

Salgia, R. ;

Clark, J. W. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)

[3] Breast cancer susceptibility genes -: BRCA1 and BRCA2 [J].

Brody, LC ;

Biesecker, BB .

MEDICINE, 1998, 77 (03) :208-226

[4] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[5] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[6] Resistance to therapy caused by intragenic deletion in BRCA2 [J].

Edwards, Stacey L. ;

Brough, Rachel ;

Lord, Christopher J. ;

Natrajan, Rachael ;

Vatcheva, Radost ;

Levine, Douglas A. ;

Boyd, Jeff ;

Reis-Filho, Jorge S. ;

Ashworth, Alan .

NATURE, 2008, 451 (7182) :1111-U8

[7] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].

Farmer, H ;

McCabe, N ;

Lord, CJ ;

Tutt, ANJ ;

Johnson, DA ;

Richardson, TB ;

Santarosa, M ;

Dillon, KJ ;

Hickson, I ;

Knights, C ;

Martin, NMB ;

Jackson, SP ;

Smith, GCM ;

Ashworth, A .

NATURE, 2005, 434 (7035) :917-921

[8] Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].

Fong, Peter C. ;

Boss, David S. ;

Yap, Timothy A. ;

Tutt, Andrew ;

Wu, Peijun ;

Mergui-Roelvink, Marja ;

Mortimer, Peter ;

Swaisland, Helen ;

Lau, Alan ;

O'Connor, Mark J. ;

Ashworth, Alan ;

Carmichael, James ;

Kaye, Stan B. ;

Schellens, Jan H. M. ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134

[9] Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [J].

Gelmon, K. A. ;

Hirte, H. W. ;

Robidoux, A. ;

Tonkin, K. S. ;

Tischkowitz, M. ;

Swenerton, K. ;

Huntsman, D. ;

Carmichael, J. ;

Macpherson, E. ;

Oza, A. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[10] Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].

Gordon, AN ;

Fleagle, JT ;

Guthrie, D ;

Parkin, DE ;

Gore, ME ;

Lacave, AJ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3312-3322

← 1 2 →